InvestorsObserver
×
News Home

Should Biotechnology Stock MiMedx Group Inc (MDXG) Be in Your Portfolio Wednesday?

Wednesday, November 22, 2023 01:09 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock MiMedx Group Inc (MDXG) Be in Your Portfolio Wednesday?

MiMedx Group Inc (MDXG) is near the top in its industry group according to InvestorsObserver. MDXG gets an overall rating of 70. That means it scores higher than 70 percent of stocks. MiMedx Group Inc gets a 91 rank in the Biotechnology industry. Biotechnology is number 53 out of 148 industries.

Overall Score - 70
MDXG has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on MDXG!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With MiMedx Group Inc Stock Today?

MiMedx Group Inc (MDXG) stock is trading at $7.59 as of 1:08 PM on Wednesday, Nov 22, a gain of $0.38, or 5.2% from the previous closing price of $7.21. The stock has traded between $7.17 and $7.64 so far today. Volume today is low. So far 342,499 shares have traded compared to average volume of 619,318 shares. Click Here to get the full Stock Report for MiMedx Group Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App